Franklin Resources Inc. reduced its stake in shares of Envista Holdings Corporation (NYSE:NVST – Free Report) by 7.8% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 8,067,810 shares of the company’s stock after selling 684,488 shares during the period. Franklin Resources Inc. owned approximately 4.91% of Envista worth $175,152,000 as of its most recent SEC filing.
A number of other hedge funds also recently made changes to their positions in NVST. Holocene Advisors LP bought a new stake in shares of Envista during the 2nd quarter worth $43,936,000. Norges Bank bought a new stake in shares of Envista during the 4th quarter worth $45,113,000. Alliancebernstein L.P. lifted its holdings in shares of Envista by 34.0% during the 2nd quarter. Alliancebernstein L.P. now owns 6,098,445 shares of the company’s stock worth $119,164,000 after acquiring an additional 1,547,656 shares during the last quarter. Balyasny Asset Management L.P. bought a new stake in shares of Envista during the 3rd quarter worth $24,260,000. Finally, Jupiter Asset Management Ltd. lifted its holdings in shares of Envista by 48.2% during the 4th quarter. Jupiter Asset Management Ltd. now owns 1,999,048 shares of the company’s stock worth $43,399,000 after acquiring an additional 650,006 shares during the last quarter.
Wall Street Analyst Weigh In
NVST has been the subject of a number of research analyst reports. Zacks Research downgraded shares of Envista from a “strong-buy” rating to a “hold” rating in a report on Monday, April 6th. Barclays lifted their price objective on shares of Envista from $24.00 to $34.00 and gave the stock an “overweight” rating in a report on Wednesday, February 11th. Wall Street Zen downgraded shares of Envista from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th. Mizuho boosted their price target on shares of Envista from $24.00 to $27.00 and gave the stock a “neutral” rating in a research note on Tuesday, February 10th. Finally, Citigroup assumed coverage on shares of Envista in a research note on Wednesday, April 15th. They issued a “neutral” rating and a $29.00 price target for the company. Six analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Envista has an average rating of “Hold” and a consensus price target of $28.83.
Envista Stock Performance
Envista stock opened at $24.58 on Wednesday. The company has a quick ratio of 2.06, a current ratio of 2.44 and a debt-to-equity ratio of 0.47. The company has a market capitalization of $4.00 billion, a PE ratio of 59.94, a P/E/G ratio of 1.33 and a beta of 0.88. The firm has a fifty day simple moving average of $25.08 and a two-hundred day simple moving average of $24.65. Envista Holdings Corporation has a twelve month low of $18.25 and a twelve month high of $30.42.
Envista (NYSE:NVST – Get Free Report) last posted its quarterly earnings results on Wednesday, May 6th. The company reported $0.36 earnings per share for the quarter, topping the consensus estimate of $0.31 by $0.05. The business had revenue of $705.50 million during the quarter, compared to the consensus estimate of $680.04 million. Envista had a net margin of 2.41% and a return on equity of 7.11%. The firm’s revenue for the quarter was up 14.4% on a year-over-year basis. During the same period in the previous year, the firm posted $0.24 earnings per share. Envista has set its FY 2026 guidance at 1.350-1.450 EPS. Research analysts expect that Envista Holdings Corporation will post 1.42 EPS for the current year.
Envista Company Profile
Envista Holdings Corporation is a global dental products company that develops, manufactures and markets a broad portfolio of dental consumables, equipment and technology solutions. Headquartered in Brea, California, Envista serves dental practitioners, specialists and laboratories in more than 150 countries. The company’s offerings span implant, orthodontic, endodontic and restorative product lines as well as digital imaging systems and practice management software.
Envista’s product brands include Nobel Biocare for dental implants and restorative solutions, Ormco for orthodontic appliances and treatment systems, Kerr for restorative and endodontic materials, KaVo for dental imaging and handpieces, and Vista for surgical drills and instruments.
See Also
- Five stocks we like better than Envista
- The Bank of Mom and Dad Is Booming—3 Stocks to Watch
- Corning Is Paving AI’s Future With Glass
- Why’s Amazon Suddenly Lagging the S&P 500, and Is It a Warning?
- Crypto Winter Is Here: 3 Stocks To Put On Ice This Summer
Want to see what other hedge funds are holding NVST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Envista Holdings Corporation (NYSE:NVST – Free Report).
Receive News & Ratings for Envista Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Envista and related companies with MarketBeat.com's FREE daily email newsletter.
